Compare NetApp Inc. (NTAP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs 10X Genomics Inc — how do they compare? NetApp Inc. trades at $237.15 (market cap $45.38B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: NetApp Inc. is far larger — about 4.5× 10X Genomics Inc's market cap, and NetApp Inc. pays a 0.9% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 56 Days and 10X Genomics Inc for 91 Days on average.
| NTAP | TXG | |
|---|---|---|
Market Cap | $45.38B | $10.07B |
Volume | 2,264,311 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $237.15 | $97.74 |
52-Week Low | $94.11 | $11.48 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | $44.34B | $9.59B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTAP trades at $231.05, down 2.03% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported Q2 2026 EPS of $2.58, beating estimates of $2.12, and maintains robust profitability with a net margin of 19.19%. Recent news highlights strategic AI partnerships with Oracle and Supermicro, enhancing its data infrastructure offerings.
Outlook remains positive driven by AI demand and earnings momentum, though valuation multiples like a P/E of 32.63 suggest premium pricing. Risks include competitive pressures and execution of new initiatives. Analyst consensus is mixed with a $219.30 price target, below the current price, indicating potential near-term consolidation.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
